Metastatic Uveal Melanoma is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Metastatic Uveal Melanoma have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Metastatic Uveal Melanoma compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Metastatic Uveal Melanoma overview

Metastatic uveal melanoma is a rare and aggressive form of cancer that originates in the pigmented cells of the eye, specifically in the uvea, which includes the iris, ciliary body, and choroid. While the primary tumor in the eye may be treatable, metastatic spread of uveal melanoma to other parts of the body, such as the liver, lungs, bones, or other organs, is associated with a poor prognosis. Uveal melanoma is the most common primary intraocular malignancy in adults. Initially, it may cause few symptoms or be asymptomatic. Common signs include changes in vision, such as blurred vision, visual disturbances, or seeing flashes of light. In some cases, a dark spot on the iris or sudden onset of floaters may be observed. Despite successful treatment of the primary tumor, up to 50% of patients with uveal melanoma will eventually develop metastatic disease, often involving the liver as the most common site of spread. Metastases to other organs, including the lungs, bones, and skin, can also occur. Risk factors for metastatic uveal melanoma include larger tumor size, older age, certain genetic mutations, and specific characteristics of the primary tumor, such as the presence of specific genetic abnormalities. Diagnosis involves a comprehensive eye examination by an ophthalmologist, which may include specialized tests such as ultrasound, fluorescein angiography, or optical coherence tomography. Confirmation of uveal melanoma may require a biopsy of the eye or fine-needle aspiration biopsy.

For a complete picture of PTSR and LoA scores for drugs in Metastatic Uveal Melanoma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.